BACKGROUND: Hypoxic-ischemic encephalopathy (HIE) remains an important cause of neonatal death and frequently leads to significant long-term disability in survivors. Therapeutic hypothermia, while beneficial, still leaves many treated infants with lifelong disabilities. Adjunctive therapies are needed, and erythropoietin (Epo) has the potential to provide additional neuroprotection. OBJECTIVES: The aim of this study was to review the current incidence, mechanism of injury, and sequelae of HIE, and to describe a new phase III randomized, placebo-controlled trial of Epo neuroprotection in term and near-term infants with moderate to severe HIE treated with therapeutic hypothermia. METHODS: This article presents an overview of HIE, neuroprotective functions of Epo, and the design of a double-blind, placebo-controlled, multicenter trial of high-dose Epo administration, enrolling 500 neonates ≥36 weeks of gestation with moderate or severe HIE diagnosed by clinical criteria. RESULTS AND CONCLUSIONS:Epo has robust neuroprotective effects in preclinical studies, and phase I/II trials suggest that multiple high doses of Epo may provide neuroprotection against brain injury in term infants. The High Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) Trial will evaluate whether high-dose Epo reduces the combined outcome of death or neurodevelopmental disability when given in conjunction with hypothermia to newborns with moderate/severe HIE.
RCT Entities:
BACKGROUND:Hypoxic-ischemicencephalopathy (HIE) remains an important cause of neonatal death and frequently leads to significant long-term disability in survivors. Therapeutic hypothermia, while beneficial, still leaves many treated infants with lifelong disabilities. Adjunctive therapies are needed, and erythropoietin (Epo) has the potential to provide additional neuroprotection. OBJECTIVES: The aim of this study was to review the current incidence, mechanism of injury, and sequelae of HIE, and to describe a new phase III randomized, placebo-controlled trial of Epo neuroprotection in term and near-term infants with moderate to severe HIE treated with therapeutic hypothermia. METHODS: This article presents an overview of HIE, neuroprotective functions of Epo, and the design of a double-blind, placebo-controlled, multicenter trial of high-dose Epo administration, enrolling 500 neonates ≥36 weeks of gestation with moderate or severe HIE diagnosed by clinical criteria. RESULTS AND CONCLUSIONS:Epo has robust neuroprotective effects in preclinical studies, and phase I/II trials suggest that multiple high doses of Epo may provide neuroprotection against brain injury in term infants. The High Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) Trial will evaluate whether high-dose Epo reduces the combined outcome of death or neurodevelopmental disability when given in conjunction with hypothermia to newborns with moderate/severe HIE.
Authors: Elizabeth E Rogers; Sonia L Bonifacio; Hannah C Glass; Sandra E Juul; Taeun Chang; Dennis E Mayock; David J Durand; Dongli Song; Anthony J Barkovich; Roberta A Ballard; Yvonne W Wu Journal: Pediatr Neurol Date: 2014-08-27 Impact factor: 3.372
Authors: Christopher M Traudt; Ronald J McPherson; Larry A Bauer; Todd L Richards; Thomas M Burbacher; Ryan M McAdams; Sandra E Juul Journal: Dev Neurosci Date: 2013-11-01 Impact factor: 2.984
Authors: Yvonne W Wu; Larry A Bauer; Roberta A Ballard; Donna M Ferriero; David V Glidden; Dennis E Mayock; Taeun Chang; David J Durand; Dongli Song; Sonia L Bonifacio; Fernando F Gonzalez; Hannah C Glass; Sandra E Juul Journal: Pediatrics Date: 2012-09-24 Impact factor: 7.124
Authors: Li Liu; Shefali Oza; Daniel Hogan; Jamie Perin; Igor Rudan; Joy E Lawn; Simon Cousens; Colin Mathers; Robert E Black Journal: Lancet Date: 2014-09-30 Impact factor: 79.321
Authors: Elliott Mark Weiss; Katherine F Guttmann; Aleksandra E Olszewski; Brooke E Magnus; Sijia Li; Scott Y H Kim; Anita R Shah; Sandra E Juul; Yvonne W Wu; Kaashif A Ahmad; Ellen Bendel-Stenzel; Natalia A Isaza; Andrea L Lampland; Amit M Mathur; Rakesh Rao; David Riley; David G Russell; Zeynep N I Salih; Carrie B Torr; Joern-Hendrik Weitkamp; Uchenna E Anani; Taeun Chang; Juanita Dudley; John Flibotte; Erin M Havrilla; Alexandra C O'Kane; Krystle Perez; Brenda J Stanley; Seema K Shah; Benjamin S Wilfond Journal: J Pediatr Date: 2021-08-14 Impact factor: 4.406
Authors: Jessica L Wisnowski; Pia Wintermark; Sonia L Bonifacio; Christopher D Smyser; A James Barkovich; A David Edwards; Linda S de Vries; Terrie E Inder; Vann Chau Journal: Semin Fetal Neonatal Med Date: 2021-10-29 Impact factor: 3.726
Authors: Yulu Song; Peter J Lally; Maria Yanez Lopez; Georg Oeltzschner; Mary Beth Nebel; Borjan Gagoski; Steven Kecskemeti; Steve C N Hui; Helge J Zöllner; Deepika Shukla; Tomoki Arichi; Enrico De Vita; Vivek Yedavalli; Sudhin Thayyil; Daniele Fallin; Douglas C Dean; P Ellen Grant; Jessica L Wisnowski; Richard A E Edden Journal: Neuroradiology Date: 2021-10-15 Impact factor: 2.995
Authors: Thomas R Wood; Phuong T Vu; Bryan A Comstock; Janessa B Law; Dennis E Mayock; Patrick J Heagerty; Thomas Burbacher; Theo K Bammler; Sandra E Juul Journal: J Cereb Blood Flow Metab Date: 2021-02-07 Impact factor: 6.200
Authors: Simerdeep K Dhillon; Guido Wassink; Christopher A Lear; Joanne O Davidson; Nicholas H G Holford; Alistair J Gunn; Laura Bennet Journal: Int J Mol Sci Date: 2020-04-25 Impact factor: 5.923